ESMO 2022 Conference Coverage
ESMO 2022: Early Decreases in KRAS Mutant Allele Frequency Predicts Clinical Benefit to the PLK1 Inhibitor Onvansertib in Combination With FOLFIRI/Bev in 2L Treatment of mCRC
By
ESMO 2022 Conference Coverage
FEATURING
Heinz-Josef Lenz
By
ESMO 2022 Conference Coverage
FEATURING
Heinz-Josef Lenz
Login to view comments.
Click here to Login
GI